AsclepiX Therapeutics Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Later Stage VC
  • (In Progress)

  • Investors
  • 12

AsclepiX Therapeutics General Information

Description

Operator of a biopharmaceutical company intended to develop a novel and durable treatment for retinal diseases. The company uses computational biology to identify potent peptide regulators of vascular homeostasis, its integrin-regulating peptides designed to inhibit neovascularization by disrupting VEGF R2 (vascular endothelial growth factor receptor 2), reducing vascular permeability and leakage by promoting TIE2 (tunica intima endothelial kinase 2) clustering at intracellular junctions, and suppress vascular inflammation by inhibiting NFkB (nuclear factor kappa B)-mediated inflammation, it is in initial Phase 1/2a clinical data in Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) demonstrated durable efficacy after one injection, it is currently advancing the Discover study which will evaluate the safety and bioactivity of AXT107 (gersizangitide) via the suprachoroidal route in subjects with nAMD, providing patients with preventive neovascularization and reduced vascular permeability.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Corporate Office
  • 5237 River Road
  • Suite 334
  • Bethesda, MD 20816
  • United States
+1 (800) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AsclepiX Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC 29-Mar-2024 0000 In Progress Clinical Trials - Phase 1
10. Later Stage VC (Series A3) 26-Jul-2023 0000 0000 0000 Completed Clinical Trials - Phase 1
9. Later Stage VC (Series A) 24-Jun-2020 0000 0000 0000 Completed Generating Revenue
8. Early Stage VC (Series A) 13-Nov-2018 000 000 0000 Completed Generating Revenue
7. Grant 01-Jan-2018 00000 Completed Generating Revenue
6. Grant 01-Jan-2017 00.00 Completed Generating Revenue
5. Grant 01-Sep-2015 00000 Completed Generating Revenue
4. Grant 24-Jul-2014 00.000 Completed Generating Revenue
3. Accelerator/Incubator 25-Jun-2014 Completed Generating Revenue
2. Grant 15-Jun-2013 $100K Completed Generating Revenue
To view AsclepiX Therapeutics’s complete valuation and funding history, request access »

AsclepiX Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A3 00,000,000 00.000000 00.00 00.00 00 00.00 00.00
Series A2 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A-1 17,752,980 $0.000100 $1.97 $1.97 1x $1.97 26.61%
To view AsclepiX Therapeutics’s complete cap table history, request access »

AsclepiX Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biopharmaceutical company intended to develop a novel and durable treatment for retinal diseases. The comp
Biotechnology
Bethesda, MD
5 As of 2024
0000
0000000000 0 0000

000000

m dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proiden
0000000000000
Redwood City, CA
000 As of 0000
00000
000000000 00000

000000

esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat
0000 000000000
San Juan Capistrano, CA
0 As of 0000
000.00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AsclepiX Therapeutics Competitors (46)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Adverum Biotechnologies Formerly VC-backed Redwood City, CA 000 00000 000000000 00000
Allegro Ophthalmics Venture Capital-Backed San Juan Capistrano, CA 0 000.00 0000000000 0 000.00
Clearside Biomedical Formerly VC-backed Alpharetta, GA 00 00000 00000000 00000
Unity Biotechnology Formerly VC-backed South San Francisco, CA 00 00000 00000000 00000
PulseSight Therapeutics Venture Capital-Backed Paris, France 00 000.00 00000000000 000.00
You’re viewing 5 of 46 competitors. Get the full list »

AsclepiX Therapeutics Patents

AsclepiX Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240226241-A1 Formulations for intraocular delivery of peptides derived from type iv collagen Pending 26-Aug-2022 000000000
AU-2020248438-A1 Compositions and methods for treating ocular disease Pending 26-Mar-2019 000000000
EP-3946418-A1 Compositions and methods for treating ocular disease Pending 26-Mar-2019 000000000 0
EP-3946418-A4 Compositions and methods for treating ocular disease Pending 26-Mar-2019 000000000 0
US-20230054032-A1 Compositions and methods for treating ocular disease Pending 26-Mar-2019 A61K38/39
To view AsclepiX Therapeutics’s complete patent history, request access »

AsclepiX Therapeutics Executive Team (8)

Name Title Board Seat
Robert Dempsey Chief Executive Officer, President & Board Member
Amir Shojaei Ph.D Chief Scientific Officer & Executive Vice President of Clinical Development
Jill Tierney Vice President of Finance & Controller
Aleksander Popel Ph.D Co-Founder & Board Observer
Jordan Green Ph.D Co-Founder & Board Member
You’re viewing 5 of 8 executive team members. Get the full list »

AsclepiX Therapeutics Board Members (11)

Name Representing Role Since
Aleksander Popel Ph.D AsclepiX Therapeutics Co-Founder & Board Observer 000 0000
Christopher Garabedian Perceptive Advisors Board Member 000 0000
Frederick Callori JD Perceptive Advisors Board Member 000 0000
Jordan Green Ph.D Self Co-Founder & Board Member 000 0000
Joshua Barer Barer & Son Capital Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

AsclepiX Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AsclepiX Therapeutics Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Hibiscus Capital Management Venture Capital Minority 000 0000 000000 0
Perceptive Advisors Hedge Fund Minority 000 0000 000000 0
Xontogeny Accelerator/Incubator Minority 000 0000 000000 0
Barer & Son Capital Venture Capital Minority 000 0000 000000 0
Piedmont Capital Partners Real Estate Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »

AsclepiX Therapeutics FAQs

  • When was AsclepiX Therapeutics founded?

    AsclepiX Therapeutics was founded in 2011.

  • Who is the founder of AsclepiX Therapeutics?

    Aleksander Popel Ph.D and Jordan Green Ph.D are the founders of AsclepiX Therapeutics.

  • Who is the CEO of AsclepiX Therapeutics?

    Robert Dempsey is the CEO of AsclepiX Therapeutics.

  • Where is AsclepiX Therapeutics headquartered?

    AsclepiX Therapeutics is headquartered in Bethesda, MD.

  • What is the size of AsclepiX Therapeutics?

    AsclepiX Therapeutics has 5 total employees.

  • What industry is AsclepiX Therapeutics in?

    AsclepiX Therapeutics’s primary industry is Biotechnology.

  • Is AsclepiX Therapeutics a private or public company?

    AsclepiX Therapeutics is a Private company.

  • What is AsclepiX Therapeutics’s current revenue?

    The current revenue for AsclepiX Therapeutics is 000000.

  • How much funding has AsclepiX Therapeutics raised over time?

    AsclepiX Therapeutics has raised $50M.

  • Who are AsclepiX Therapeutics’s investors?

    Hibiscus Capital Management, Perceptive Advisors, Xontogeny, Barer & Son Capital, and Piedmont Capital Partners are 5 of 12 investors who have invested in AsclepiX Therapeutics.

  • Who are AsclepiX Therapeutics’s competitors?

    Adverum Biotechnologies, Allegro Ophthalmics, Clearside Biomedical, Unity Biotechnology, and PulseSight Therapeutics are some of the 46 competitors of AsclepiX Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »